Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Novastan: Better late than never

Despite underestimating the pitfalls of conducting clinical trials with its Novastan argatroban direct thrombin inhibitor, Texas Biotechnology Corp. finally has its approvable letter from the FDA to treat or prevent heparin induced thrombocytopenia (HIT). In hindsight, TXB believes that a better understanding of the clinical trial process was needed from the outset. Specifically, the company did not

Read the full 579 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers